>
Former White House Advisor: "Trump to Release $150 Trillion Endowment"
The Mayo Clinic just tried to pull a fast one on the Trump administration...
'Cyborg 1.0': World's First Robocop Debuts With Facial Recognition And 360° Camera Visio
Dr. Aseem Malhotra Joins Alex Jones Live In-Studio! Top Medical Advisor To HHS Sec. RFK Jr. Gives...
'Cyborg 1.0': World's First Robocop Debuts With Facial Recognition And 360° Camera Visio
The Immense Complexity of a Brain is Mapped in 3D for the First Time:
SpaceX, Palantir and Anduril Partnership Competing for the US Golden Dome Missile Defense Contracts
US government announces it has achieved ability to 'manipulate space and time' with new tech
Scientists reach pivotal breakthrough in quest for limitless energy:
Kawasaki CORLEO Walks Like a Robot, Rides Like a Bike!
World's Smallest Pacemaker is Made for Newborns, Activated by Light, and Requires No Surgery
Barrel-rotor flying car prototype begins flight testing
Coin-sized nuclear 3V battery with 50-year lifespan enters mass production
BREAKTHROUGH Testing Soon for Starship's Point-to-Point Flights: The Future of Transportation
The study's lead researcher, Dr. Robert Naviaux of the San Diego School of Medicine is an internationally known expert in human genetics, inborn errors of metabolism, metabolomics, and mitochondrial medicine. He is the discoverer of the cause of Alpers syndrome — the oldest Mendelian form of mitochondrial disease — and the developer of the first DNA test to diagnose it. Naviaux is, by far, one of the most qualified people in the world to conduct this study.
During his research, Naviaux noted the transformative results of the drug suramin which was first developed in 1916 and used as an anti-parasitic drug for treating African sleeping sickness and river blindness. After giving a single dose of suramin to boys with autism, between the ages of five and 14, Naviaux recorded something incredible — their symptoms were significantly alleviated.
"After the single dose, it was almost like a roadblock had been released," he said. "If the future studies show that there's continued health benefits, this could be a game-changer for families with autism."